Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Pieter van Paassen, Leo Heunks et al.|The Lancet Respiratory Medicine|2022Cited by 143
Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)Michael Bauer, A. Weyland, Gernot Marx et al.|Critical Care Explorations|2021Cited by 36